Firmicutes spores

Cell therapyexperimental

Clinical trial activity

4 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0

Earliest trial started May 1, 2015 (NCT02437500)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • microbiotaTissue restoration

    microbiota tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • ser-109

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03183128Phase 3Jun 1, 2017Seres Therapeutics
NCT03183141Phase 3Jun 1, 2017Seres Therapeutics
NCT02437487Phase 2May 1, 2015INC Research, Seres Therapeutics
NCT02437500N/AMay 1, 2015INC Research, Seres Therapeutics
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Seres TherapeuticsFor profit4432015
INC ResearchFor profit2022015
2 organizations
Page 1 / 1